• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
Addiction Treatment Forum

Addiction Treatment Forum

Addiction Treatment Forum reports on substance use news of interest to opioid treatment programs and patients in medication-assisted treatment.

  • Newsletter
  • Addiction Resources
  • Rx Methadone & Safety
  • Patient Brochures
  • Events
  • Related Websites

Orphan Drugs For Opioid Use Disorder: An Abuse Of The Orphan Drug Act

July 29, 2019 by ATForum

In November 2017, the drug company Indivior received Food and Drug Administration (FDA) approval for Sublocade, a once-monthly buprenorphine injection for patients with opioid use disorder. In December 2018, Braeburn Inc. received FDA approval for a similar product but could not sell it due to Indivior’s marketing exclusivity period. Typically, the FDA grants three years of marketing exclusivity for new formulations of previously approved drugs such as buprenorphine. However, in a controversial decision, the FDA approved Sublocade under a 1994 orphan designation for one of the company’s prior buprenorphine products. Consequently, under the Orphan Drug Act of 1983, Sublocade is entitled to a seven-year period of marketing exclusivity (so-called orphan drug exclusivity).

Despite this entitlement, it is currently unclear whether the FDA has granted orphan drug exclusivity. To prevent this possibility, Braeburn Inc. filed a Citizen Petition in April 2019, calling for the FDA to revoke Sublocade’s orphan designation and refuse to grant orphan drug exclusivity (or withdraw exclusivity if already granted). This petition—which is separate from a lawsuit that Braeburn Inc. Filed to overturn a three-year marketing exclusivity period for Sublocade—argues that Sublocade is not a bona fide orphan drug because opioid use disorder, a disease that affects more than two million Americans, is not a rare orphan disease.

As of the time of writing, the FDA has not decided on the petition. By statute, the agency has 150 days to respond. We will provide policy context for this controversy and argue that the FDA should not allow orphan drug exclusivity for Sublocade.

Source: Health Affairs blog

Read more at: https://www.healthaffairs.org/do/10.1377/hblog20190724.795814/full/

Filed Under: 2019, 320, News Updates

Primary Sidebar

Upcoming Events

AATOD
April 10-14, 2021
Las Vegas, NV
https://www.eventscribe.com/2021/AATOD/

The Americam Society of Addiction Medicine (ASAM) 51th Annual Medical-Scientific Conference
Thursday, April 22, 2021 to Saturday, April 24, 2021
Virtual
https://www.drugabuse.gov/news-events/meetings-events/2021/04/americam-society-addiction-medicine-asam-51th-annual-medical-scientific-conference

APA 2021 Annual Meeting
Saturday, May 1, 2021 to Wednesday, May 5, 2021
Los Angeles, California
https://www.drugabuse.gov/news-events/meetings-events/2021/05/apa-2021-annual-meeting

View More Upcoming Events…

ATForum.com

  • Newsletter
  • News Updates
  • Addiction Resources
  • Rx Methadone & Safety
  • Patient Education Brochures
  • Events
  • Related Websites

Addiction Resources

  • Addiction and Recovery
  • Addiction Treatment Forum
  • Books and Booklets of Interest
  • Drug Screening and Testing
  • Evidence-Based Addiction Medicine
  • Government
  • Health Care Reform
  • Hepatitis, HIV/AIDS
  • Medication-Assisted Treatment
  • Mental Health
  • Miscellaneous
  • Online Continuing Education Free Training Modules

Footer

Addiction Treatment Forum is produced by an independent medical communications agency. Commercial advertising is not accepted.
Published by Clinco Communications, Inc.
About Us
Contact Us
Privacy Policy
Terms of Use
Follow Us

This educational resource is supported by Hikma Pharmaceuticals USA Inc.

Sign up for News!

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: Clinco Communications, Inc., 1808 N. Arlington Heights Road, Arlington Heights, IL, 60004, http://www.atforum.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

© 2021 Addiction Treatment Forum · All Rights Reserved